NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93rd Congress, taking place on May 4-7, 2025 in Glasgow, UK.
Late-breaker oral presentation details are as follows:
Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized Trial
Session Name: Late Breaker Session: Clinical
Oral Presentation Date and Time: Wednesday, May 5, 2025, 12:00-12:15 PM BST (7:00-7:15 AM ET)
Location: William Harvey Hall
Title: Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Session Name: Late Breaker Session: Clinical
Oral Presentation Date and Time: Wednesday, May 5, 2025, 12:15-12:30 PM BST (7:15-7:30 AM ET)
Location: Will Harvey Hall
Additional session details are as follows:
Title: Obicetrapib Reduces Atherosclerosis and Vascular Inflammation, Mainly by Reducing Non-HDL Cholesterol, Improves Lesion Stability and Adds to the Beneficial Effects of Ezetimibe
Session Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and Outcomes
Presentation Date and Time: Monday, May 5, 2025, 1:58-2:05 PM BST (8:58-9:05 AM ET)
Location: Station 7
Title: Obicetrapib Alone and in Combination with Ezetimibe Increases Reverse Cholesterol Transport and Does Not Affect VLDL Production
Session Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and Outcomes
Presentation Date and Time: Monday, May 5, 2025, 2:05-2:12 PM BST (9:05-9:12 AM ET)
Location: Station 7
Title: Low-Dose Obicetrapib Significantly Increases Concentrations of Lipophilic Antioxidants, ApoE, and S1P in HDL Subfractions
Session Name: SaaG Session: Lipid Lowering Therapies and Advances in Vascular Therapeutics
Presentation Date and Time: Monday, May 5, 2025, 2:19-2:26 PM BST (9:19-9:26 AM ET)
Location: Station 4
Title: Obicetrapib Significantly Increases Plasma and High-Density Lipoprotein (HDL) Levels of Lipophilic Antioxidants
Session Name: SaaG Session: Lipoprotein Dynamics: HDL to Remnants
Presentation Date and Time: Monday, May 5, 2025, 3:17-3:24 PM BST (10:17-10:24 AM ET)
Location: Station 3
Title: Efficacy and Safety of Combination Obicetrapib with Moderate-Dose Statins
Session Name: Poster Networking Sessions
Presentation Date and Time: Monday, May 5 & Tuesday, May 6, 2025, 5:20 - 6:50 PM BST (12:17-1:24 PM ET)
Location: Poster Board #246, Exhibition Hall
Title: Safety and Efficacy of Cholesteryl Ester Transfer Protein Inhibition: From Genetics to Outcome Trials
Session Name: Workshop: New risk factors for atherosclerotic disease
Presentation Date and Time: Wednesday, May 7, 2025, 12:20 -12:30 PM BST (7:17-8:24 AM ET)
Location: James Black Hall
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$20.03 |
| Daily Volume: | 479,381 |
| Market Cap: | US$2.140B |
March 31, 2025 February 26, 2025 January 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
